Fair Value Calculator Fair Value Calculator
EN DE

2500 (2500) Fair Value & Analysis

Healthcare · Market cap HK$609M

2 2500 2500 · HK
PriceHK$1.35
Fair ValueHK$3.09
Upside+128.9%
Quality37/100
Watch 2500 for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range HK$2.31 – HK$4.62

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price +3.8% over the past month.

Price vs Fair Value (12 months)

HK$4.95 HK$1.12 Fair Value HK$3.09 Jun 2025 Jul 2026

12‑month range HK$1.12 – HK$4.95 · fair‑value band HK$2.31 – HK$4.62 · the HK$1.35 price screens below the HK$3.09 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2500 (2500) currently trades at HK$1.35, while our model-based Fair Value estimate is HK$3.09 — implying the stock looks roughly 128.9% undervalued today. We read business quality at 37/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Trailing-twelve-month revenue stands at HK$307M. Revenue declined 50.2% year over year. It earns a return on equity of -20.5%. Net debt stands at HK$41.4M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$307M
Revenue growth (YoY) -50.2%
Net margin -133%
Return on equity -20.5%
Free cash flow −HK$332M FY2025
Operating margin -174%
More key figures
EPS (TTM) HK$-0.3100
Net debt HK$41.4M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2500 reported revenue of HK$307M in FY2025 versus HK$416M in FY2021, a compound −7.3%/yr. Reported net income was −HK$408M in FY2025.

Revenue −7.3%/yr
FY21 HK$416M
FY22 HK$406M
FY23 HK$491M
FY24 HK$471M
FY25 HK$307M
Net income
FY21 −HK$374M
FY22 −HK$1.1B
FY23 −HK$704M
FY24 −HK$714M
FY25 −HK$408M

Is 2500 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
ABT ABT 1,600 MXN 1,231 MXN -23%
Abbott Laboratories, ABTT34 R$39.41 R$30.42 -23%
Stryker Corporation S1YK34 R$79.18 R$43.78 -45%
Medtronic plc MDT $81.67 $60.02 -27%
Boston Scientific Corporation B1SX34 R$229.30 R$43.33 -81%
Edwards Lifesciences Corporation EW $85.98 $41.02 -52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 2500 (2500) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$3.09 versus a price of HK$1.35 — about +129% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 2500?
Our model-based fair value for 2500 is HK$3.09 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.35.
What is the quality score of 2500?
2500 has a Quality Score of 37/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 2500 (2500)?
2500 reported trailing-twelve-month revenue of about HK$307M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 2500?
The net profit margin of 2500 is about -132.9%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.